Cargando…

Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19

BACKGROUND: Low-dose chest CT (LDCT) showed high sensitivity and ability to quantify lung involvement of COVID-19 pneumopathy. The aim of this study was to describe the prevalence and risk factors for lung involvement in 247 patients with a visual score and assess the prevalence of incidental findin...

Descripción completa

Detalles Bibliográficos
Autores principales: Castelli, Maxime, Maurin, Arnaud, Bartoli, Axel, Dassa, Michael, Marchi, Baptiste, Finance, Julie, Lagier, Jean-Christophe, Million, Matthieu, Parola, Philippe, Brouqui, Philippe, Raoult, Didier, Cortaredona, Sebastien, Jacquier, Alexis, Gaubert, Jean-Yves, Habert, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670109/
https://www.ncbi.nlm.nih.gov/pubmed/33201409
http://dx.doi.org/10.1186/s13244-020-00939-7
_version_ 1783610673387798528
author Castelli, Maxime
Maurin, Arnaud
Bartoli, Axel
Dassa, Michael
Marchi, Baptiste
Finance, Julie
Lagier, Jean-Christophe
Million, Matthieu
Parola, Philippe
Brouqui, Philippe
Raoult, Didier
Cortaredona, Sebastien
Jacquier, Alexis
Gaubert, Jean-Yves
Habert, Paul
author_facet Castelli, Maxime
Maurin, Arnaud
Bartoli, Axel
Dassa, Michael
Marchi, Baptiste
Finance, Julie
Lagier, Jean-Christophe
Million, Matthieu
Parola, Philippe
Brouqui, Philippe
Raoult, Didier
Cortaredona, Sebastien
Jacquier, Alexis
Gaubert, Jean-Yves
Habert, Paul
author_sort Castelli, Maxime
collection PubMed
description BACKGROUND: Low-dose chest CT (LDCT) showed high sensitivity and ability to quantify lung involvement of COVID-19 pneumopathy. The aim of this study was to describe the prevalence and risk factors for lung involvement in 247 patients with a visual score and assess the prevalence of incidental findings. METHODS: For 12 days in March 2020, 250 patients with RT-PCR positive tests and who underwent LDCT were prospectively included. Clinical and imaging findings were recorded. The extent of lung involvement was quantified using a score ranging from 0 to 40. A logistic regression model was used to explore factors associated with a score ≥ 10. RESULTS: A total of 247 patients were analyzed; 138 (54%) showed lung involvement. The mean score was 4.5 ± 6.5, and the mean score for patients with lung involvement was 8.1 ± 6.8 [1–31]. The mean age was 43 ± 15 years, with 121 males (48%) and 17 asymptomatic patients (7%). Multivariate analysis showed that age > 54 years (odds ratio 4.4[2.0–9.6] p < 0.001) and diabetes (4.7[1.0–22.1] p = 0.049) were risk factors for a score ≥ 10. Multivariate analysis including symptoms showed that only age > 54 years (4.1[1.7–10.0] p = 0.002) was a risk factor for a score ≥ 10. Rhinitis (0.3[0.1–0.7] p = 0.005) and anosmia (0.3[0.1–0.9] p = 0.043) were protective against lung involvement. Incidental imaging findings were found in 19% of patients, with a need for follow-up in 0.6%. CONCLUSION: The prevalence of lung involvement was 54% in a predominantly paucisymptomatic population. Age ≥ 55 years and diabetes were risk factors for significant parenchymal lung involvement. Rhinitis and anosmia were protective against LDCT abnormalities.
format Online
Article
Text
id pubmed-7670109
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-76701092020-11-18 Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19 Castelli, Maxime Maurin, Arnaud Bartoli, Axel Dassa, Michael Marchi, Baptiste Finance, Julie Lagier, Jean-Christophe Million, Matthieu Parola, Philippe Brouqui, Philippe Raoult, Didier Cortaredona, Sebastien Jacquier, Alexis Gaubert, Jean-Yves Habert, Paul Insights Imaging Original Article BACKGROUND: Low-dose chest CT (LDCT) showed high sensitivity and ability to quantify lung involvement of COVID-19 pneumopathy. The aim of this study was to describe the prevalence and risk factors for lung involvement in 247 patients with a visual score and assess the prevalence of incidental findings. METHODS: For 12 days in March 2020, 250 patients with RT-PCR positive tests and who underwent LDCT were prospectively included. Clinical and imaging findings were recorded. The extent of lung involvement was quantified using a score ranging from 0 to 40. A logistic regression model was used to explore factors associated with a score ≥ 10. RESULTS: A total of 247 patients were analyzed; 138 (54%) showed lung involvement. The mean score was 4.5 ± 6.5, and the mean score for patients with lung involvement was 8.1 ± 6.8 [1–31]. The mean age was 43 ± 15 years, with 121 males (48%) and 17 asymptomatic patients (7%). Multivariate analysis showed that age > 54 years (odds ratio 4.4[2.0–9.6] p < 0.001) and diabetes (4.7[1.0–22.1] p = 0.049) were risk factors for a score ≥ 10. Multivariate analysis including symptoms showed that only age > 54 years (4.1[1.7–10.0] p = 0.002) was a risk factor for a score ≥ 10. Rhinitis (0.3[0.1–0.7] p = 0.005) and anosmia (0.3[0.1–0.9] p = 0.043) were protective against lung involvement. Incidental imaging findings were found in 19% of patients, with a need for follow-up in 0.6%. CONCLUSION: The prevalence of lung involvement was 54% in a predominantly paucisymptomatic population. Age ≥ 55 years and diabetes were risk factors for significant parenchymal lung involvement. Rhinitis and anosmia were protective against LDCT abnormalities. Springer International Publishing 2020-11-17 /pmc/articles/PMC7670109/ /pubmed/33201409 http://dx.doi.org/10.1186/s13244-020-00939-7 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Castelli, Maxime
Maurin, Arnaud
Bartoli, Axel
Dassa, Michael
Marchi, Baptiste
Finance, Julie
Lagier, Jean-Christophe
Million, Matthieu
Parola, Philippe
Brouqui, Philippe
Raoult, Didier
Cortaredona, Sebastien
Jacquier, Alexis
Gaubert, Jean-Yves
Habert, Paul
Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19
title Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19
title_full Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19
title_fullStr Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19
title_full_unstemmed Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19
title_short Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19
title_sort prevalence and risk factors for lung involvement on low-dose chest ct (ldct) in a paucisymptomatic population of 247 patients affected by covid-19
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670109/
https://www.ncbi.nlm.nih.gov/pubmed/33201409
http://dx.doi.org/10.1186/s13244-020-00939-7
work_keys_str_mv AT castellimaxime prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT maurinarnaud prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT bartoliaxel prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT dassamichael prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT marchibaptiste prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT financejulie prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT lagierjeanchristophe prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT millionmatthieu prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT parolaphilippe prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT brouquiphilippe prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT raoultdidier prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT cortaredonasebastien prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT jacquieralexis prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT gaubertjeanyves prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19
AT habertpaul prevalenceandriskfactorsforlunginvolvementonlowdosechestctldctinapaucisymptomaticpopulationof247patientsaffectedbycovid19